Skip to main content
. 2018 Aug 21;119(6):724–736. doi: 10.1038/s41416-018-0233-4

Table 3.

Summary of long non-coding RNAs biomarkers for TSCC

Studied biomarkers Sample Type Sample size Significant biomarkersa Detection method Expression Clinical implication Level of evidence (LoE)a References
Group A studies
  lncRNA UCA1 Tissue 94 lncRNA UCA1 qRT-PCRb Poor prognosis (Increased risk metastasis) + 89
  lnc-AL355149.1-1,lnc-PPP2R4-5, lnc-SPRR2D-1, Tissue 32 lnc-AL355149.1-1 qRT-PCR Advanced T stages +
  lnc-MBL2-4:3,lnc-MAN1A2-1,lnc-FAM46A-1, lnc-STXBP5-1, and lnc-MBL2-4:1 lnc-MBL2-4:3 Poor prognosis (Increased risk metastasis) + 90
  lncRNA MEG3 Tissue 76 lncRNA MEG3 qRT-PCR Poor Prognosis + 91
  lncRNA HOTTIP Tissue 86 lncRNA HOTTIP qRT-PCR Poor Prognosis + 92
  lncRNA NKILA Tissue 96 lncRNA (NKILA) qRT-PCR Poor prognosis (Increased risk metastasis) + 93
  lncRNA TUG1 Tissue 27 lncRNA (TUG1) qRT-PCR Detection + 94
  lncRNA TUC338 Tissue 25 lncRNA TUC338 qRT-PCR Enhanced proliferation + 95
  lnc RNA 152 (LINC00152 Tissue 15 197 LINC00152 qRT-PCR & in situ hybridization Detection & prognosis + 96
18 2
  lncRNA 673 (LINC00673) Tissue 202 217 LINC00673 qRT-PCR Poor prognosis (Increased risk metastasis) + 97
15
Group B studies
  MALAT1 Tissue & cell lines (CAL27 and SCC-25) 127 MALAT1 qRT-PCR Poor prognosis (Increased risk metastasis) ++ 98
  MALAT1 Tongue cancer cell lines and tissue 30 MALAT1 qRT-PCR Poor prognosis (Increased risk metastasis) 99

− no significant association between biomarker and clinical value, + number of studies with statistical significant outcome = 1, ++ number of studies with consistent outcome = 2, +++ number of studies with consistent outcome ≥3, ↑increased, ↓decreased

aOnly significant biomarker(s) used in ranking level of evidence

bqRT-PCR: quantitative real-time polymerase chain reaction